The COVID-19 pandemic highlighted the role of ACE2 in lung physiology and its upregulation in NSCLC (55), which inspired us to exploit ACE2 overexpression as a novel target for receptor-mediated drug delivery in NSCLC cells. The gene discussed is ACE2; the disease is non-small cell lung carcinoma.